We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Simple Saliva DNA Test Identifies Prostate Cancer Patients at Risk for Radiation Toxicity

By LabMedica International staff writers
Posted on 09 Jul 2024
Print article
Image: PROSTOX can predict an increased risk of late genitourinary toxicity from specific radiation therapies (Photo courtesy of MiraKind)
Image: PROSTOX can predict an increased risk of late genitourinary toxicity from specific radiation therapies (Photo courtesy of MiraKind)

Radiation therapy is the standard treatment for prostate cancer, but it can lead to long-lasting side effects like urinary and bowel complications, significantly affecting patients' quality of life. Globally, men with prostate cancer endure the highest number of years living with disabilities resulting from treatment side effects, underscoring both the high prevalence of the disease and the effectiveness of modern therapy in achieving high cure rates. Now, researchers are further advancing their work in personalizing cancer treatment to enhance the quality of life for prostate cancer patients by predicting and preventing severe long-term side effects caused by radiation therapy.

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center (Los Angeles, CA, USA) have received a USD 1.8 million grant from the National Cancer Institute (NCI, Bethesda, MD, USA) to validate and leverage biomarkers that predict adverse side effects from radiation therapy. Their study targets specific genetic markers known as mirSNPs, which are promising in predicting side effects from cancer treatments. A critical biomarker identified by the team, PROSTOX, has been shown to predict late genitourinary toxicity following advanced radiation therapy. PROSTOX is effective in predicting toxicity from two radiation therapy types: Stereotactic body radiation therapy (SBRT), which administers radiation in high doses over 5-7 sessions, and conventionally fractionated radiation therapy (CFRT), involving 35-45 sessions.

This test enables the assessment of whether a patient is at low or high risk for late genitourinary toxicity following SBRT or CFRT. Understanding the risk level can assist patients and physicians in selecting the most appropriate and safest treatment strategy. The researchers aim to further validate the predictive accuracy of PROSTOX in more patient groups. Additionally, they plan to explore the biological variations among patients with these biomarkers and assess the potential of highly targeted adaptive radiotherapy to minimize these and other side effects for all patients.

“By understanding the mirSNP genetic markers that predispose patients to adverse side effects from cancer therapy we can tailor these therapies to minimize harm and maximize efficacy,” said co-investigator Dr. Joanne Weidhaas, professor of radiation oncology, vice chair and head of translational research and co-developer of the PROSTOX test. “This work has the potential to improve the lives of countless patients.”

Related Links:
UCLA Health Jonsson Comprehensive Cancer Center
MiraDx
NCI

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Hemoglobin Testing System
VARIANTnbs

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: The new DxC 500i Clinical Analyzer is an integrated clinical chemistry and immunoassay analyzer (Photo courtesy of Beckman Coulter Diagnostics)

Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability

As global healthcare systems increasingly shift towards networked laboratory operational models to enhance efficiency and patient access, there is a greater need for innovative solutions tailored to the... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Microbiology

view channel
Image: The Simplexa C. auris direct kit is a real-time polymerase chain reaction assay run on the LIAISON MDX instrument (Photo courtesy of Diasorin)

Novel Molecular Test to Help Prevent and Control Multi Drug-Resistant Fungal Pathogen in Healthcare Settings

Candida auris (C. auris) is a rapidly emerging multi drug-resistant fungal pathogen that is commonly found in healthcare environments, where it presents a challenge due to its ability to asymptomatically... Read more

Pathology

view channel
Image: Color-enhanced scanning electron micrograph showing Salmonella Typhimurium (red) invading cultured human cells (Photo courtesy of Rocky Mountain Laboratories, NIAID, NIH)

AI Identifies Drug-Resistant Typhoid-Like Infection from Microscopy Images within Hours

Antimicrobial resistance is becoming a serious global health concern, making many infections increasingly difficult to treat and limiting available treatment options. This escalation in resistance raises... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.